Aclaris Therapeutics (NASDAQ:ACRS) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.16) by 6.25 percent. This is a 15.38 percent decrease over losses of $(0.13) per share from the same period last year. The company reported quarterly sales of $1.629 million which beat the analyst consensus estimate of $1.383 million by 17.80 percent. This is a 8.33 percent decrease over sales of $1.777 million the same period last year.